Motley Fool Estimates Tilray Now Only Generates 35% of Revenue from Cannabis

This Cannabis Giant Only Generates 35% of Its Revenue From Its Marijuana Products. Here’s Where the Rest Comes From…. is what they say and worth noting the Hexo acquisition to boost the numbers for last year

A breakdown of Tilray’s sales

In January, Tilray Brands posted record revenue of $194 million for the second quarter of fiscal 2024, which ended Nov. 30. And while cannabis is a key part of its operations, the majority of Tilray’s revenue comes from other area of its business.

Here’s a breakdown of Tilray’s segments and their respective revenue growth last quarter:

Segment Q2 Fiscal 2024 Revenue Year-Over-Year Growth
Cannabis $67.1 million 35%
Distribution $67.2 million 12%
Beverage $46.5 million 117%
Wellness $12.9 million 2%

Data source: Company filings. Table by author.

Cannabis revenue was up an impressive 35% last quarter, but in June of last year, Tilray acquired a key rival, Hexo, which has helped give its revenue a boost from the prior-year numbers.

Tilray’s distribution business involves the purchase and resale of pharmaceutical products. A key part of that business is CC Pharma, a leading pharmaceutical distributor based in Germany that Tilray owns. CC Pharma also distributes medical cannabis, offering Tilray a path to becoming a leading cannabis operator in Europe.

Read full article

Primary Sponsor


Karma Koala Podcast

Top Marijuana Blog